The rate of prostate-specific antigen (PSA) testing for prostate cancer has been increasing in the United Kingdom since the early 1990s (Gavin et al, 2004; Melia et al, 2004; NHS Cancer Screening Programmes, 2004). Here, KLK3 is linked to prostate carcinoma.